HYPERFIBRINOGENEMIA - AN IMPORTANT RISK FACTOR FOR VASCULAR COMPLICATIONS IN DIABETES

被引:151
作者
GANDA, OP
ARKIN, CF
机构
[1] NEW ENGLAND DEACONESS HOSP, DEPT MED, BOSTON, MA 02215 USA
[2] NEW ENGLAND DEACONESS HOSP, DEPT PATHOL, BOSTON, MA 02215 USA
[3] HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA
关键词
D O I
10.2337/diacare.15.10.1245
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To evaluate the determinants of elevated fibrinogen levels and the impact of hyperfibrinogenemia on vascular complications in diabetes. RESEARCH DESIGN AND METHODS - Plasma fibrinogen, glucose, HbA1, and lipids were measured in 116 ambulatory type I and type II diabetic patients with (n = 59) or without (n = 57) clinical evidence of micro- or macrovascular complications. In 56 of these patients, factor VII activity and CRP also were measured. Univariate and multivariate data analyses were conducted. RESULTS - Overall mean +/- SE fibrinogen levels in patients (339 +/- 7.3 mg/dl) were elevated markedly compared with control subjects (248 +/- 9.1 mg/dl). Fibrinogen levels were elevated disproportionately in patients with type II diabetes (P < 0.0001), hypertension (P = 0.0001), obesity (P < 0.0001), and vascular complications (P < 0.0001). Fibrinogen was correlated significantly with age (P < 0.001), cholesterol (P = 0.002), CRP (P < 0.001), and factor VII activity (P = 0.032), but not with plasma glucose, triglycerides, HDL cholesterol, or disease duration. Stepwise multiple regression analyses revealed that type II diabetes and presence of vascular complications were major determinants of fibrinogen. For vascular complications, fibrinogen emerged as one of only three independent predictors, the other two being diabetes duration and hypertension. CONCLUSIONS - Fibrinogen frequently is elevated in diabetes and is an independent predictor of vascular complications.
引用
收藏
页码:1245 / 1250
页数:6
相关论文
共 35 条
[1]  
[Anonymous], 1989, DIABETES CARE, V12, P573
[2]  
BANGA JD, 1986, CLIN HAEMATOL, V15, P465
[3]  
BLOM M, 1976, CLIN CHEM, V22, P657
[4]   INHIBITION OF HEPARIN-CATALYZED HUMAN ANTITHROMBIN III ACTIVITY BY NONENZYMATIC GLYCOSYLATION - POSSIBLE ROLE IN FIBRIN DEPOSITION IN DIABETES [J].
BROWNLEE, M ;
VLASSARA, H ;
CERAMI, A .
DIABETES, 1984, 33 (06) :532-535
[5]  
CLAUSS A., 1957, ACTA HAEMATOL, V17, P237
[6]   PLASMA COFACTORS OF PLATELET-FUNCTION - CORRELATION WITH DIABETIC-RETINOPATHY AND HEMOGLOBINS ALA-C - STUDIES IN DIABETIC-PATIENTS AND NORMAL PERSONS [J].
COLLER, BS ;
FRANK, RN ;
MILTON, RC ;
GRALNICK, HR .
ANNALS OF INTERNAL MEDICINE, 1978, 88 (03) :311-316
[7]   VASCULAR-DISEASE IN DIABETES - PATHOPHYSIOLOGICAL MECHANISMS AND THERAPY [J].
COLWELL, JA ;
HALUSHKA, PV ;
SARJI, KE ;
LOPESVIRELLA, MF ;
SAGEL, J .
ARCHIVES OF INTERNAL MEDICINE, 1979, 139 (02) :225-230
[8]   THROMBOSIS AS A FACTOR IN THE PATHOGENESIS OF CORONARY ATHEROSCLEROSIS [J].
DUGUID, JB .
JOURNAL OF PATHOLOGY AND BACTERIOLOGY, 1946, 58 (02) :207-&
[9]   ALTERATIONS IN PLASMA-LIPIDS IN THE PRESENCE OF MILD GLUCOSE-INTOLERANCE IN THE OFFSPRING OF 2 TYPE-II DIABETIC PARENTS [J].
GANDA, OP ;
SOELDNER, JS ;
GLEASON, RE .
DIABETES CARE, 1985, 8 (03) :254-260
[10]  
GANDA OP, 1985, JOSLINS DIABETES MEL, P158